Elsevier

The Lancet

Volume 340, Issue 8832, 5 December 1992, Pages 1363-1369
The Lancet

ORIGINAL ARTICLES
Early versus delayed neonatal administration of a synthetic surfactant — the judgment of OSIRIS

https://doi.org/10.1016/0140-6736(92)92557-VGet rights and content

Abstract

Although exogenous surfactants are of known efficacy in the prevention and treatment of respiratory distress syndrome (RDS), questions remain about the best regimens. During 1990-91, 6774 babies were recruited to an international multicentre trial to assess when administration of Exosurf, a synthetic surfactant, should be started and how often it should be given. The clinical outcome is known for 6757 (99·7%) infants. 2690 babies, judged to be at high risk of RDS when less than 2 hours of age, were randomly allocated to either early administration or delayed selective administration; 96% versus 73% received surfactant, at median ages of 118 and 182 min. The risk of death or dependence on extra oxygen at the expected date of delivery was 16% (95% Cl 25% to 7%) lower among infants allocated early administration. Early administration was also associated with a 32% lower risk of pneumothorax. These 2690 infants were further randomised in a factorial design to either two doses of surfactant 12 hours apart, or the option of third and fourth doses at 12-36 hour intervals if signs of RDS persisted or recurred. 4067 other infants who later developed RDS were also recruited to this comparison, giving a total of 3376 infants allocated up-to-four doses (of whom, 45% received more than two) and 3381 allocated two doses. The outcome was similar in the two groups in respect of death, long-term oxygen dependence, and other major morbidity, even in secondary analyses restricted to infants who met the criteria for additional administration. There were more reports of poorly tolerated administration in the up-to-four doses group but no clear increase in serious morbidity, such as pulmonary haemorrhage. The OSI RIS trial suggests that early administration of surfactant to an estimated 32 babies, when compared with treatment of established RDS, would prevent 1 baby from dying and another from being dependent on extra oxygen long-term, but would entail the additional use of surfactant in 8 of these babies. It provides no evidence that a regimen including the option of third and fourth doses when signs of RDS persist or recur is clinically superior to a regimen of two doses.

References (17)

There are more references available in the full text version of this article.

Cited by (228)

  • Pharmacologic Therapies I: Surfactant Therapy

    2017, Assisted Ventilation of the Neonate: An Evidence-Based Approach to Newborn Respiratory Care: Sixth Edition
  • Design and conduct of a large obstetric or neonatal randomized controlled trial

    2015, Seminars in Fetal and Neonatal Medicine
    Citation Excerpt :

    Researchers should explain who was blinded and how. However, blinding is often not feasible, e.g. in trials of obstetric management [17,18,71,85], neonatal surfactant [114,115] or respiratory support [113,116,117]. Lack of blinding can lead to bias, but double blinding is not a prerequisite for high quality.

  • Defining neonatal hypoglycaemia: A continuing debate

    2014, Seminars in Fetal and Neonatal Medicine
    Citation Excerpt :

    However, subsequent studies using the same approach failed to support this finding [12,22,23]. Mindful of the need to confirm the findings by Lucas et al. [19], a group of clinicians and nurses in the north of England (the Northern Neonatal Nursing Initiative Trial Group) initiated an observational study along with two other randomised trials [24,25]; all nested into the prospective study of early neonatal care and neurodevelopmental outcome in preterm infants. This prospective study included all 781 babies of <32 weeks of gestation, born in 1990 and 1991 to mothers residing in the north of England, and all the surviving babies had their blood glucose levels measured (by glucose oxidase assay) every morning at a fixed time in the first 10 days of life.

  • Surfactant Replacement: Present and Future Present and Future

    2012, The Newborn Lung: Neonatology Questions and Controversies Expert Consult
  • CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomised trials

    2012, International Journal of Surgery
    Citation Excerpt :

    Example—“The risk of oxygen dependence or death was reduced by 16% (95% CI 25%–7%). The absolute difference was −6.3% (95% CI −9.9% to −2.7%); early administration to an estimated 16 babies would therefore prevent 1 baby dying or being long-term dependent on oxygen” (also see Table 7).242 Explanation—When the primary outcome is binary, both the relative effect (risk ratio (relative risk) or odds ratio) and the absolute effect (risk difference) should be reported (with confidence intervals), as neither the relative measure nor the absolute measure alone gives a complete picture of the effect and its implications.

View all citing articles on Scopus

Correspondence to Perinatal Trials Service, National Perinatal Epidemiology Unit, Radcliffe Infirmary, Oxford OX2 6HE, UK

View full text